Petrova I V, Leshchenko G M, Bystritskaia T F
Vestn Dermatol Venerol. 1989(5):67-9.
Thirty-four patients with chronic pyoderma have been examined. Fifteen of these have been treated with mielopid (18 mg per course). Immunologic and clinical examinations carried out in 3-10 months after therapy have demonstrated a wide-spectrum immunostimulating action of the new drug.
对34例慢性脓皮病患者进行了检查。其中15例接受了米洛匹德治疗（每疗程18毫克）。治疗后3至10个月进行的免疫和临床检查表明，这种新药具有广泛的免疫刺激作用。
